Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Orphan drug developer Retrophin completes $25mm PIPE

Executive Summary

First-time and returning institutional backers participated in a $25mm PIPE for Retrophin Inc. (rare pediatric disease therapeutics for neurological, renal, and muscular conditions). Investors bought 5.6mm shares for $4.50 (a 12% discount) and received five-year warrants to purchase 2.8mm shares at $6.00. The placement agents were Stifel Nicolaus & Co. and Roth Capital Partners. The company concurrently disclosed that it was negotiating an exclusive US license to a large pharmaco’s IP to develop a product for autism and schizophrenia. Retrophin will use the new funds to attempt to put this agreement in place.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies